Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 21, 2026.

Impact of Gut Microbiota and Microbiota-Related Metabolites on Hyperlipidemia

Xiaokang Jia, Wen Xu, Lei Zhang and 3 more

Frontiers in Cellular and Infection Microbiology · 2021 · Review · CC BY

doi:10.3389/fcimb.2021.634780

Abstract

Hyperlipidemia, defined as the presence of excess fat or lipids in the blood, has been considered as a high-risk factor and key indicator of many metabolic diseases. The gut microbiota has been reported playing a vital role in regulating host lipid metabolism. The pathogenic role of gut microbiota in the development of hyperlipidemia has been revealed through fecal microbiota transplantation experiment to germ-free mice. The effector mechanism of microbiota-related metabolites such as bile acids, lipopolysaccharide, and short-chain fatty acids in the regulation of hyperlipidemia has been partially unveiled. Moreover, studies on gut-microbiota-targeted hyperlipidemia interventions, including the use of prebiotics, probiotics, fecal microbiota transplantation, and natural herbal medicines, also have shown their efficacy in the treatment of hyperlipidemia. In this review, we summarize the relationship between gut microbiota and hyperlipidemia, the impact of gut microbiota and microbiota-related metabolites on the development and progression of hyperlipidemia, and the potential therapeutic management of hyperlipidemia targeted at gut microbiota.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 21, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

With the improvement of living standards and the aging of the global population, the incidence of metabolic diseases such as obesity, diabetes, arteriosclerosis, stroke, coronary heart disease, and myocardial infarction is increasing rapidly. Notably, dyslipidemia or hyperlipidemia is a common feature among these chronic diseases. Hyperlipidemia is characterized by high levels of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and triglycerides (TG) and a low level of high-density lipoprotein cholesterol (HDL-C). The etiology of hyperlipidemia is determined by a combination of genetic and environmental factors, such as diet, lifestyle, and even geographic location, but the underlying mechanism remains unclear. The incidence and mortality rates of hyperlipidemia and its complications are also increasing rapidly, accounting for nearly half of the deaths worldwide. Early treatment of hyperlipidemia can effectively prevent the occurrence of related diseases.

Recent studies have shown that gut microbiota is a critical environmental factor in the regulation of body metabolism, contributing to the occurrence and development of chronic diseases, such as obesity, diabetes, and atherosclerosis. Gut microbiota represents the huge community of bacteria residing in the gastrointestinal tract. The total amount of gut microbiota genes is 100 times that of human genes and is known as the “second genome” of humans. Gut microbiota serves several functions in host metabolism, such as supplementing body nutrition, promoting immunity, and protecting the intestinal barrier. Given its regulatory role in host lipid metabolism, gut microbiota has been highly associated with hyperlipidemia and related diseases. Attribute to the germ-free animal model, the casual role of gut microbiota it the development has been established. Moreover, gut-microbiota metabolites such as short-chain fatty acids (SCFAs), lipopolysaccharide (LPS), and bile acids (BAs) have been discovered in the occurrence and development of hyperlipidemia.

In the present paper, we propose that gut microbiota is the key to the development of hyperlipidemia and related chronic diseases. Understanding the interaction between gut microbiota and hyperlipidemia is important to prevent and improve hyperlipidemia-related diseases.

Dysbiosis of Gut Microbiota in Individuals With Hyperlipidemia

The disturbance of lipid metabolism could induce changes the intestinal environment, which could induce the dysbiosis of internal microflora. The development of high-throughput technology enables us to deepen the understanding of the composition of different ecosystems in the human gut and the role of metabolites.

It has been reported that individuals with hyperlipidemia exhibit disturbed structure and function of gut microbiota. Children and adolescents with hyperlipidemia show low levels of fecal acetate, butyrate, and propionate, which are associated with SCFA-producing bacteria, such as those from families Lachnospiraceae and Ruminococcaceae and genera Akkermansia, Bacteroides, Roseburia, and Faecalibacterium. A randomized controlled trial has shown that, compared with the feces of healthy individuals, the feces of patients with metabolic syndrome(charaterized by hyperlipidemia) contain lower abundance of potential probiotics such as Bifidobacterium, Lactobacillus, Faecalibacterium prausnitzii and Roseburia but higher abundance of LPS-producing bacteria (Escherichia coli and Enterobacter cloacae). Studies based on the conventionalization of germ-free (GF) and conventionally raised (CV) animals recognize the special role of the intestinal microbiota in host metabolism. Compared with healthy mice, diabetic db/db mice with lipid-metabolism disorder have lower levels of butyrate-producing bacteria (e.g., Fecalibacterium prausnitzii, Eubacterium rectale, and Roseburia intestinalis) and higher levels of opportunistic pathogens (e.g., Clostridium hathewayi, Clostridium ramosum, and Eggerthella lenta). The feces of rats with hyperlipidemia contains significantly more LPS-producing bacteria (e.g., Bilophila and Sutterella) and mucosa-damaging bacteria (Bilophila and Akkermansia muciniphila). Hyperlipidemia is also associated with microbial structure and function in the ileum, which can transform glycine or taurine-conjugated BAs into unconjugated BAs. Other studies have shown that the structure of gut microbial in hyperlipidemia rats is changed, which reduces the excretion of BAS in the cecum. The gut microbial trimethylamine N-oxide (TMAO) pathway is also closely linked to host cholesterol and BA metabolism, TMAO can reduce the expression of the key enzyme CYP7A1 in bile acid synthesis, reduce the bile acid pool, inhibit cholesterol transport, and cause the accumulation of cholesterol in the cell.

At present, a clear consensus about the imbalances in gut microbiota composition under hyperlipidemia remains to be achieved, which may attributed to the fact that gut microbiota shares similar functions across species. At the metabolite level, individuals with hyperlipidemia show low levels of SCFAs, high levels of LPS and TMAO, and changed BA pool.

Gut Microbiota Regulates Lipid-Metabolism Homeostasis and Contributes to the Development of Hyperlipidemia

Normal gut microbiota is essential in maintaining lipid-metabolism homeostasis. Compared with CV mice, GF mice show a lower level of TG in the adipose tissue and the liver but a higher level of TG in the circulatory system. When fed with high-fat, high-carbohydrate Western diet, GF mice have less hypercholesterolemia and more cholesterol excretion in the liver and feces. After a single gavage of olive oil in GF and conventional mice, GF mice show higher serum TG and longer metabolism time of TG. The exposure of mice to a low-dose endotoxin (LPS) significantly increases the level of serum TG. Bacteria with LPS-producing ability could increase serum endotoxin load and aggravate inflammatory response, leading to fat accumulation. These findings revealed that gut microbiota regulates lipid-metabolism homeostasis and contributes to the development of hyperlipidemia.

The Underlying Mechanism Between Gut Microbiota and Lipid Metabolism

Diet is the main factor affecting the diversity of intestinal bacteria. The Western diet represented by high fat and high sugar can change the composition of intestinal flora and directly promote the occurrence of lipid metabolism disorder. Several pathways have been proposed in the regulation of lipid metabolism mediated by gut microbiota (Figure 1). Gut microbiota and the related metabolites could protect or disrupt the integrity of the intestine, thereby affecting the function of peripheral tissues. Gut microbiota can regulate the brain–gut axis through immune response and the vagus nerve. Imbalances in gut microbiota can lead to the proliferation of potential pathogenic bacteria, affect immune homeostasis, and induce a pro-inflammatory local immune response. This phenomenon is accompanied by inflammatory cytokine and adipokine production [e.g., tumor necrosis factor-α, interleukin (IL)-6 and IL-1β, and leptin]. At the same time, the increase in intestinal permeability caused by a high-fat diet (HFD) can aggravate this situation. In addition to its effects on peripheral immune cells, gut microbiota can also reportedly regulate immune cells (microglia) located in the brain, causing microglia activation and neuroinflammation and affecting the hypothalamic neurons that regulate appetite. Consequently, food intake is reduced and energy consumption is increased. Another study has shown that vagotomy in animal models results in decreased anorexia hormone signaling and subsequently increased food intake and body-weight gain. The metabolites produced by gut microbiota can activate enteroendocrine cells to release intestinal hormones and can directly interact with the enteric nervous system and its innervating vagus nerve. The generated local signals can then be transmitted through sensory neural circuits to the brain regions involved in eating behavior, affecting appetite and satiety. Gut microbiota can also change the integrity of intestinal epithelial cells and the intestine, regulate cholesterol metabolism in the liver, promote lipid oxidation in muscles, and regulate lipid storage in adipose tissue, thereby regulating lipids’ metabolic balance.

A balanced gut microbiota (the microorganisms of the gut microbiota stay in the mutualistic symbioses and create a stable intestinal microsystem) contributes to the maintenance of lipid homeostasis, referred to various tissues and organs, including mediating satiety in the brain through microglia and vagus nerves, regulating cholesterol metabolism in the liver, promoting lipid oxidation in the muscle and energy storage in the adipose tissue, and maintaining the integrity of the intestinal barrier. In contrast, the dysbiosis of gut microbiota could disturb the lipid metabolism through mechanisms mentioned above.

Metabolites of Gut Microbiota and Hyperlipidemia

Gut microbiota can ferment food residues, produce a large number of metabolites, and regulate biological functions in the human body. Host health is closely related to microbial metabolites, including SCFAs, BAs, LPS, TMAO, polyphenols, polyamines, indoles, vitamins, and amino acids. The present study emphasizes the relationship of hyperlipidemia to BAs, LPS, and SCFA.

BAs and Hyperlipidemia

Primary BAs are synthesized by cholesterol in the liver and enter the intestinal tract to participate in lipid digestion. The majority of BAs are reabsorbed in the ileum and transported to the liver through the portal vein, whereas the minority enters the large intestine. Different types of BAs exert different regulatory effects on lipid metabolism. Gut microbiota can regulate lipid metabolism by balancing the BA pool and composition. Under the action of gut microbiota in the terminal ileum and colon, primary BAs are converted into secondary BAs by microbial-related bile-salt hydrolase (BSH) and 7-dehydroxylase. In patients with hyperlipidemia, the synthesis of total BAs is increased, the BA pool is enlarged, and the ratio of primary to secondary BAs in the intestine is significantly changed. In mice treated with antibiotics, BA secretion in the liver is increased three times, whereas that in excreta is significantly decreased. Antibiotics also significantly increase hepatic BA secretion while reduce BA excretion. BAs regulate lipid metabolism and energy homeostasis by activating G-protein-coupled receptor-5 (TGR5) and farnesoid X receptor (FXR) (Figure 2). As an agonist of TGR5, BAs can directly activate TGR5 and its downstream energy-consumption-related signal pathways in brown adipocytes, thereby promoting the energy consumption of adipose tissue and muscle in mice. FXR also participates in the regulation of BA enterohepatic circulation and lipid metabolism, which exerts a tissue-specific effect. BAs can inhibit intestinal FXR signaling, increase fibroblast growth factor 15/19 (FGF15/19) production, and affect the secretion of cell-surface fibroblast growth factor receptor 4, ultimately promoting BA synthesis and decrease cholesterol levels. BAs can also inhibit adipogenesis by activating FXR in the liver. Compared with intestinal-specific FXR knockout mice, liver-specific FXR gene knockout mice show poor ability to maintain blood lipid. Intestine-specific FXR gene knockout can reduce liver fat accumulation, inhibit intestinal FXR expression, reduce hepatic gluconeogenesis, and improve glucose and lipid-metabolism disorder in mice fed with HFD.

BAs also can shape the structure of gut microbiota. The biotransformation of BAs plays a certain role in the detoxification of gut microbiota so that bacteria can avoid being killed by BAs. When combined with phospholipids on the bacterial cell membrane, BAs can exert a destructive role in bacterial cells, resist bacterial adhesion, and neutralize endotoxins; high concentrations of conjugated BAs exert a direct antibacterial effect. Meanwhile, different bacteria have different degrees of sensitivity to BAs. HFD rich in saturated fatty acids can promote BA secretion, thereby changing the living environment of bacteria. Consequently, the gut-microbiota structure becomes changed, the growth of some potential pathogens in the intestine is promoted, and the lipid metabolism of the host is adversely affected.

In brown adipose tissue, the activation of TGR5 induces the intracellular accumulation of cAMP, followed by the downstream activation of its signaling pathways, such as the activation of DIO2. DIO2 converts the prohormone T4 into the active hormone T3 and increases metabolic rates. Consistent with this feature, the activation of TGR5 enhances the expression of a series of downstream genes related to the energy expenditure of TGR5 including D2, UCP1, PRDM16, and PGC-1α in vivo and in vitro. In the liver, BAs combine with FXR to activate the FXR-SHP signaling pathway. In the intestine, BSH enzymes are produced in intestinal microbes and function to hydrolyze conjugated BAs into unconjugated ones. The suppression of BSH microbes results in the accumulation of conjugated BAs, the downregulation of FXR, the inhibition of the FXR-FGF15/19 signaling pathway, and the regulation of cholesterol synthesis.

cAMP: cyclic adenosine monophosphate, DIO2: deiodinase, iodothyronine, Type II, T3: tri-iodothyronine, T4: thyroxine, UCP: uncoupling protein, PRDM16: PR domain-containing 16, PGC1α: peroxisome proliferator-activated receptor gamma coactivator 1 alpha, CYP7A1: cholesterol 7α-hydroxylase, CYP8B1: sterol 12α-hydroxylase. CYP27A1: steroid 27-hydroxylase, CYP7B1: oxysterol 7α-hydroxylase, SHP: small heterodimer partner.

LPS and Hyperlipidemia

LPS, also known as endotoxin, is an essential structural compound of the outer membrane of Gram-negative bacteria. After the death and lysis of bacteria, LPS is released into the intestinal environment and enter the circulatory system through the “leaky gut” (an increased intestinal permeability). High concentrations of LPS could induce endoxemia characterized by serious nonspecific immune response. LPS also promotes the redistribution of nutrients in the host defense during the acute phase, and blood lipids play a protective role by neutralizing the level of inflammatory cytokines. HFD, fatty acid exposure, and low-dose LPS could induce metabolic endotoxemia, which features chronic inflammation, insulin resistance, and lipid-metabolism disorder. However, supplementing HFD with antibiotics to reduce the production and blood inflow of intestinal LPS could improve the above symptoms of metabolic disorders. The systemic inflammatory responses induced by HFD are primarily attributed to the increase in the blood level of LPS. Serum LPS levels are higher in patients with obesity and mice with HFD-induced obesity than in normal controls. The HFD-induced dysbiosis of gut microbiome can damage the intestinal mucosal barrier and trigger the release of LPS into the blood. LPS can promote the infiltration of inflammatory cells and the expression of inflammatory factors in adipose tissue. Furthermore, mice lacking toll-like receptors 4 receptor and cluster-of-differentiation 14 (the receptor of LPS) are resistant to HFD- or LPS-induced hyperinsulinemia, insulin resistance, and steatosis. These results confirm that HFD feeding changes gut microbiota, promotes metabolic endotoxemia, and triggers the development of metabolic disorders (Figure 3).

In the intestine, HFD feeding can increase Gram-negative bacteria, increase the LPS content, and decrease the tight-junction proteins ZO-1 and occludin, thereby affecting the permeability and integrity of intestinal epithelial cells. LPS entering the blood can be recognized and bound by LPS-binding protein and then form an LPS/CD14 complex with the CD14 of mononuclear macrophages, leading to a series of intracellular reactions through TLR-4. Consequently, inflammatory factors are expressed and released, thereby reducing the ability of the liver, adipose, and muscle to regulate lipid metabolism, causing the body's lipid-metabolism disorder.

TLR4: toll-like receptors 4 receptor, CD14: cluster-of-differentiation 14, ZO-1:zonula occluden 1

SCFAs and Hyperlipidemia

SCFAs, fermented by gut microbes from dietary fiber, are primarily composed of acetic, propionic, butyric, isobutyric, valeric, and isovaleric. Diverse genus such as Bifidobacterium, Lactobacillus, Bacteroides, and Faecalibacterium can produce SCFAs. SCFAs are quickly and efficiently absorbed in the colon and cecum, whereas only 5%–10% of SCFAs are excreted with feces. SCFAs can be utilized as direct energy source by intestinal epithelial cells and liver. The liver can absorb about 30% of SCFAs from the portal vein, which can promote lipid production and cholesterol synthesis. Notably, SCFAs (acetate, butyrate, and propionate) can regulate lipid metabolism in the body. Once produced, SCFAs are readily absorbed and utilized in the body. Butyrate is largely utilized by the colonic epithelium as an energy source, and propionate is primarily utilized by the liver, whereas a significant amount of acetate enters systemic circulation and reaches peripheral tissues. SCFAs could act as a regulating signal of energy metabolism through the gut–brain axis and the adenosine monophosphate-activated protein kinase (AMPK) pathway to improve dyslipidemia. By binding to G-protein-coupled receptor, SCFAs could induce the release of hormones, which could increase satiety and reduce food intake. Moreover, elevated leptin level could regulate lipid metabolism through signal regulation. The absorption of acetate and propionate by the liver also activates the AMPK pathway and inhibits fatty acid, cholesterol, and TG synthesis. An animal study has shown that mice with insulin resistance induced by an HFD results in significantly increased amount of acetate in the body, thereby activating the parasympathetic nervous system, promoting glucose-stimulated insulin secretion, and increasing the appetite, and eventually leading to imbalanced lipid metabolism. Meanwhile, the combination of butyrate and propionate with GPR43, a G-protein-coupled receptor (GPCR), can inhibit the decomposition of fatty acids, promote the secretion of the best known fat hormone leptin, increase energy release, and inhibit the synthesis of fat cells, which reduce lipid metabolism in mice; these effects disappear in GPR43-knockout mice. The addition of exogenous sodium butyrate could improve insulin sensitivity in HFD-induced insulin resistance mice by promoting mitochondrial function, peroxisome proliferator-activated receptorγcoactivator-1 (PGC-1) expression, and fatty acid oxidation. However, some studies have reported that butyrate plays an opposite role in lipid metabolism, which requires further discussion. Thus, SCFAs can regulate energy metabolism to improve dyslipidemia (Figure 4).

The brain could sense the microbial metabolites not only via release of hormones such as PYY, GLP-1 and LEP after SCFAs binding to G-protein-coupled receptors (GPCRs) GPR41 (also known as Ffar3) and GPR43 (also known as Ffar2) in fat cells and enteroendocrine L-cells but also through faster neuronal signaling, which decreased food intake, suppressed the activity of orexigenic neurons that expressed neuropeptide Y in the hypothalamus and raised the sympathetic activity. Elevated plasma contents of NA induced gene expression of uncoupling proteins (UCPs) capable of dissipating the proton gradient to generate heat instead of ATP synthase. Additionally, acetate and propionate taken up by the liver were used as substrates for lipogenesis and gluconeogenesis, which increased energy dissipation. As a result, energy charge (EC) lowered in the liver and 5′AMP-activated protein kinase (AMPK) became activated because AMP binding to γ subunit of AMPK promoted a conformational change and exposed the catalytic domain on the α subunit. Phosphorylated AMPK acted on downstream target proteins and showed functions of inhibiting synthesis of fatty acids, cholesterol and triglycerides, and activating fatty acid uptake.

Treatment of Hyperlipidemia Targeted at Gut Microbiota

In the clinical setting, the medication treatment for hyperlipidemia is delivered largely through four classes of drugs: cholesterol-lowering agent (statins, cholesterol absorption inhibitors, probucol, and bile acid sequestrants), TG-lowering agent (fibrates, niacin, and omega-3 fatty acid), some emerging therapeutic agents [lomitapide, mipomersen, alirocumab, and evolocumab], and natural herbal medicines. Clinical studies have found that statins can affect gut microbiome during treatment, but few studies have focused on the effect of other lipid-lowering drugs on the gut microbiome of the intestine, which is also a limitation in this field. Given the evidence supporting the role of intestinal microbiota in hyperlipidemia, understanding how we can beneficially modify microbiota has become increasingly important. This section summarizes the main preventive and therapeutic interventions modulating gut microbiome (Table 1).

Prebiotics

Prebiotics are organic substances that are not digested and absorbed by the host but selectively promote the metabolism and proliferation of beneficial bacteria in the body, thereby improving host health. After reaching the colon, prebiotics are decomposed and utilized, promoting the growth of colonic microbiota, where they play an important role in improving the intestinal microecology and regulating lipid metabolism. Additionally, prebiotics can improve lipid metabolism by boosting probiotics and producing SCFAs. Different types of prebiotics include isomalto-oligosaccharide, fructooligosaccharide, galacto-oligosaccharide (GOS), xylooligosaccharide, lactulooligosaccharide, soybean oligosaccharide, and inulin. Inulin-type fructans regulate gut microbiota activities and reduce cholesterol and triglycerides. Different types of lactose-derivatives such as GOS, lactosucrose, and tagatose can effectively inhibit the expression of fat-forming genes and enzymes, promote the combination of cholesterol and probiotics, reduce the cholesterol level, and promote the transformation of BA enzyme and lipid metabolism to regulate lipid level. Red gram prebiotics can reduce the TG, TC, and HDL-C levels in hyperlipidemia-model rats. By changing the composition of gut microbiota through prebiotics, the mediated effect of GLP-2 can improve the intestinal-barrier function, reduce the amount of endotoxin into the blood, and improve the metabolism of blood lipids. A meta-analysis and a study supports that inulin can modulate lipid metabolism by regulating gut microbiota. A clinical trial has shown that prebiotics can increase breath-hydrogen excretion (a marker of gut-microbiota fermentation) by approximately threefold, increase plasma GLP-1 and PYY concentrations, and lower hunger rates. Interestingly, some juice and tea extracts are also considered to have prebiotic effects. A controlled clinical trial has shown that the daily intake of 300 mL of orange juice in 10 women can significantly improve blood lipids and increase the abundance of beneficial bacteria in the intestinal flora, suggesting that orange juice may act as a prebiotic. The EGCG3’’Me in oolong tea is a potential prebiotic, which ameliorates HFD-induced gut dysbiosis and significantly decreases the ratio of Firmicutes to Bacteroidetes. Green tea extract combined with isomalto-oligosaccharides can effectively prevent HFD-induced obesity and fat accumulation in liver and muscle, effectively regulate liver metabolism related to lipid metabolism, and prevent the HFD-induced increase in LPS and pro-inflammatory factors in the circulatory system, which may be due to the increased abundance of beneficial bacteria, thereby restoring the ratio of Firmicutes to Bacteroides and increasing the ratio of Prevotella to Bacteroides. In summary, the mechanism by which prebiotics improve the body’s metabolism may be to improve the composition of the gut microbiome, improve the intestinal barrier function, and show a potential beneficial effect on the regulation of lipid metabolism.

Probiotics

Probiotics is a general term for microorganisms that can improve the microecological balance of the host and play a beneficial role in it. Probiotics such as Bifidobacterium, Lactobacillus, and yeast can regulate appetite, obesity, and the cardiovascular system. Probiotics in the intestine can balance the amount of metabolites (BAs, LPS, and SFCAs) in the intestine, which can reduce liver cholesterol synthesis and, consequently, the blood lipid content. Mixed feeding of probiotics can reduce the levels of TG, TC, and fatty acids in hyperlipidemic hamsters. Interestingly, single strains have the same effect. Animal studies has shown that Lactobacillus reuteri 263, Lactobacillus fermentum MTCC: 5898, and Lactobacillus casei YBJ02 are potential probiotics that can reduce the level of blood lipids in the body. Butyrate-producing probiotics also induce peroxisomal activity and improve lipid metabolism. Consistent with animal experiments, probiotic supplementation also significantly reduces serum TC and LDL-C in patients with hyperlipidemia. A 12-week randomized, double-blind, placebo-controlled clinical trial has shown that the combination of three Lactobacillus plantarum strains can reduce blood cholesterol in patients. Additionally, a study involving 70 healthy adults has demonstrated that the daily supplementation of Lactobacillus plantarum Q180 can significantly improve blood-lipid indicators such as LDL-C and TC after meals by adjusting the composition of the intestinal flora. These studies reveal that probiotics can improve the level of TC, TG, HDL-C, and LDL-C by promoting the growth of probiotics, regulating related metabolites.

Fecal Microbiota Transplantation

FMT is the process of transferring functional bacteria in the feces of healthy people to the intestinal tract of patients in a certain way to regulate gut microbiota. The goal of FMT is to restore the healthy diversity of gut microbiota and provide effective treatment for diseases inside and outside the intestinal tract. FMT has been successful in treating Clostridium difficile infections in several trials. In recent years, FMT has also been supposed as a potential therapy to improve lipid metabolism. The transplantation of fecal bacteria from healthy mice to diet-induced obese mice improves the gut microbiota composition, function, and metabolism of obese mice. An animal study has found that the transplantation of resveratrol–microbiota to HFD mice can modulate lipid metabolism, stimulate the development of beige adipocytes in WAT, reduce inflammation, and improve intestinal-barrier function. In a new study published in Gastroenterology, 90 patients with abdominally obese or dyslipidemia have been randomly given three different dietary interventions for 6 months. After the intervention, the patients’ own fecal microbiota has been made into capsules for subsequent FMT. Results show that autologous FMT could significantly inhibit the rebound of body weight, waist circumference, and insulin level.

Natural Herbal Medicines

Increasing evidence shows that several natural herbal medicines can effectively improve dyslipidemia by regulating gut microbiota. Rhizoma Coptidis (RC) alkaloids can reduce the body-weight gain and serum TC, TG, and LDL-C levels of B6 mice. RC alkaloid feeding significantly increases the abundance of Sporobacter termitidis, Alcaligenes faecalis, and A. muciniphila while suppressing the abundance of E. coli, Desulfovibrio C21_c20, and Parabacteroides distasonis in mouse gut. Berberine may exert its lipid-lowering by promoting the production of butyrate and inhibiting the activity of BSH in gut microbiota, significantly increasing the levels of tauro-conjugated bile acids, and inhibit ileal FXR signal transduction pathway. A multicentric randomized clinical trial has shown that an herbal formula consisting of eight herbs may ameliorate type-2 diabetes with hyperlipidemia by enriching beneficial bacteria, such as Blautia and Faecalibacterium spp. Polysaccharides isolated from Hirsutella sinensis can promote the growth of specific intestinal bacteria, such as Parabacteroides goldsteinii, thereby improving obesity and adipose tissue thermogenesis, enhancing intestinal integrity and reducing levels of inflammation and insulin resistance. in mice. Theabrownin from Pu’er tea and blueberry extracts can reshape the intestinal flora of HFD mice, regulate BA pools, and activate BA receptors to lower cholesterol.

Prospect

Overwhelming evidence shows that changes in the abundance and composition of gut microbiota are generally linked to numerous hyperlipidemia-related diseases, including obesity, diabetes, arteriosclerosis, stroke, coronary heart disease, and myocardial infarction, among others. With the development of sequencing technology and the application of GF models in recent years, research on gut microbiota and microbiota-related metabolites has been greatly developed. Accordingly, the role and mechanism of gut microbiota in hyperlipidemia development have also been gradually revealed. New therapeutic approaches that target gut microbes for the treatment and prevention of hyperlipidemia represent exciting areas of investigation. Gut microbiota participates in the occurrence and development of hyperlipidemia by regulating the storage, decomposition, and distribution of lipids. Targeted therapy based on gut microbiota can effectively improve hyperlipidemia and its complications. The association and extensive plasticity of gut microbiota and microbiota-related metabolites with hyperlipidemia makes gut microbiota a potential marker for disease prediction and diagnosis, as well as a target for disease prevention and treatment. These treatments include probiotics, prebiotics, or FMT, among others, which may be used in the future to terraform the microbial community and alter its functional output for the betterment of the host. With increasing awareness of the relationship between the gut microbiome and hyperlipidemia-related diseases, we can hold high expectations for the clinical application of gut-microbiome modulation.

Author Contributions

Conceptualization, XJ and WX. Funding acquisition, WX and SW. Methodology, XL and LZ. Project administration, XJ and SW. Writing – original draft, XJ and WX. Writing – review and editing, RW and SW. All authors contributed to the article and approved the submitted version.

Funding

This work was supported by the National Natural Science Foundation of China (81773956, 81872990, and 82004149), the Provincial Natural Science Foundation of Fujian (2019I0016), and the Young and Middle-aged Backbone Program of Fujian Provincial Health Commission (2018-ZQN-65).

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References 152

  1. 1.

    Aguilar-Salinas C. A. Díaz-Polanco A. Quintana E. (2002 ). Genetic Factors Play an Important Role in the Pathogenesis of Hyperlipidemia Post-Transplantation. Am. J. Kidney Dis. 40, 169–177.

    Not in our library10.1053/ajkd.2002.33926

  2. 2.

    Ardawi M. S. Newsholme E. A. (1985 ). Fuel Utilization in Colonocytes of the Rat. Biochem. J. 231, 713–719.

    Not in our library10.1042/bj2310713

  3. 3.

    Bäckhed F. Ding H. Wang T. Hooper L. V. Koh G. Y. Nagy A.. (2004 ). The Gut Microbiota as an Environmental Factor That Regulates Fat Storage. Proc. Natl. Acad. Sci. U.S.A101(44), 15718–15723.

    Not in our library10.1073/pnas.0407076101

  4. 4.

    Bäckhed F. Manchester J. K. Semenkovich C. F. Gordon J. I. (2007 ). Mechanisms Underlying the Resistance to Diet-Induced Obesity in Germ-Free Mice. Proc. Natl. Acad. Sci. U.S.A. 104, 979–984.

    Not in our library10.1073/pnas.0605374104

  5. 5.

    Baigent C. Keech A. Kearney P. M. Blackwell L. Buck G. Pollicino C.. (2005 ). Efficacy and Safety of Cholesterol-Lowering Treatment: Prospective Meta-Analysis of Data From 90,056 Participants in 14 Randomised Trials of Statins. Lancet366, 1267–1278.

    Not in our library10.1016/s0140-6736(05)67394-1

  6. 6.

    Bartolomaeus H. Balogh A. Yakoub M. Homann S. Markó L. Höges S.. (2019 ). Short-Chain Fatty Acid Propionate Protects From Hypertensive Cardiovascular Damage. Circulation139, 1407–1421.

    Not in our library10.1161/circulationaha.118.036652

  7. 7.

    Beigneux A. P. Moser A. H. Shigenaga J. K. Grunfeld C. Feingold K. R. (2000 ). The Acute Phase Response Is Associated With Retinoid X Receptor Repression in Rodent Liver. J. Biol. Chem. 275, 16390–16399.

    Not in our library10.1074/jbc.m000953200

  8. 8.

    Bender E. (2020 ). Could a Bacteria-Stuffed Pill Cure Autoimmune Diseases? Nature 577, S12–S13.

    Not in our library10.1038/d41586-020-00197-z

  9. 9.

    Benjamin E. J. Virani S. S. Callaway C. W. (2018 ). Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association. Circulation 137, e67–e492.

    Not in our library10.1161/cir.0000000000000558

  10. 10.

    Bergman E. N. (1990 ). Energy Contributions of Volatile Fatty Acids From the Gastrointestinal Tract in Various Species. Physiol. Rev. 70, 567–590.

    Not in our library10.1152/physrev.1990.70.2.567

  11. 11.

    Bloemen J. G. Venema K. van de Poll M. C. Olde Damink S. W. Buurman W. A. Dejong C. H. (2009 ). Short Chain Fatty Acids Exchange Across the Gut and Liver in Humans Measured at Surgery. Clin. Nutr. (Edinburgh Scotland) 28, 657–661.

    Not in our library10.1016/j.clnu.2009.05.011

  12. 12.

    Brahe L. K. Astrup A. Larsen L. H. (2016 ). Can We Prevent Obesity-Related Metabolic Diseases by Dietary Modulation of the Gut Microbiota? Adv. Nutr. 7, 90–101.

    Not in our library10.3945/an.115.010587

  13. 13.
    Implication of gut microbiota metabolites in cardiovascular and metabolic diseases · 2018
    No notice
  14. 14.

    Broeders E. P. Nascimento E. B. Havekes B. Brans B. Roumans K. H. Tailleux A. (2015 ). The Bile Acid Chenodeoxycholic Acid Increases Human Brown Adipose Tissue Activity. Cell Metab. 22, 418–426.

    Not in our library10.1016/j.cmet.2015.07.002

  15. 15.

    Caesar R. Reigstad C. S. Bäckhed H. K. Reinhardt C. Ketonen M. Lundén GÖ. (2012 ). Gut-Derived Lipopolysaccharide Augments Adipose Macrophage Accumulation But Is Not Essential for Impaired Glucose or Insulin Tolerance in Mice. Gut61, 1701–1707.

    Not in our library10.1136/gutjnl-2011-301689

  16. 16.

    Canfora E. E. Jocken J. W. Blaak E. E. (2015 ). Short-Chain Fatty Acids in Control of Body Weight and Insulin Sensitivity. Nature Reviews. Endocrinology 11, 577–591.

    Not in our library10.1038/nrendo.2015.128

  17. 17.

    Cani P. D. Amar J. Iglesias M. A. Poggi M. Knauf C. Bastelica D. (2007 ). Metabolic Endotoxemia Initiates Obesity and Insulin Resis-Tance. Diabetes 56, 1761–1772.

    Not in our library10.2337/db06-1491

  18. 18.

    Cani P. D. Bibiloni R. Knauf C. Waget A. Neyrinck A. M. Delzenne N. M.. (2008 ). Changes in Gut Microbiota Control Metabolic Endotoxemia-Induced Inflammation in High-Fat Diet-Induced Obesity and Diabetes in Mice. Diabetes57, 1470–1481.

    Not in our library10.2337/db07-1403

  19. 19.

    Cani P. D. Lecourt E. Dewulf E. M. Sohet F. M. Pachikian B. D. Naslain D.. (2009 ). Gut Microbiota Fermentation of Prebiotics Increases Satietogenic and Incretin Gut Peptide Production With Consequences for Appetite Sensation and Glucose Response After a Meal. Am. J. Clin. Nutr.90, 1236–1243.

    Not in our library10.2337/db07-1403

  20. 20.
    Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability · 2009
    No notice
  21. 21.

    Cariou B. Chetiveaux M. Zaïr Y. Pouteau E. Disse E. Guyomarc’h-Delasalle B.. (2011 ). Fasting Plasma Chenodeoxycholic Acid and Cholic Acid Concentrations are Inversely Correlated With Insulin Sensitivity in Adults. Nutr. Metab. (Lond.)8, 48.

    Not in our library10.1186/1743-7075-8-48

  22. 22.

    Chambers E. S. Morrison D. J. Frost G. (2015 ). Control of Appetite and Energy Intake by SCFA: What Are the Potential Underlying Mechanisms? Proc. Nutr. Soc. 74, 328–336.

    Not in our library10.1017/s0029665114001657

  23. 23.

    Chapman M. J. Ginsberg H. N. Amarenco P. Tybjærg-Hansen A. Watts G. F. European Atherosclerosis Society Consensus Panel (2011 ). Triglyceride-Rich Lipoproteins and High-Density Lipoprotein Cholesterol in Patients at High Risk of Cardiovascular Disease: Evidence and Guidance for Management. Eur. Heart J. 32 (11), 1345–1361.

    Not in our library10.1093/eurheartj/ehr112

  24. 24.

    Cheik N. C. Rossi E. A. Guerra R. L. Tenório N. M. Oller do Nascimento C. M. Viana F. P.. (2008 ). Effects of a Fer-Ment Soy Product on the Adipocyte Area Reduction and Dyslipidemia Control in Hypercholesterolemic Adult Male Rats. Lipids Health Dis.7, 50.

    Not in our library10.1186/1476-511x-7-50

  25. 25.

    Chen J. J. Xie J. Zeng B. H. Li W. W. Bai S. J. Zhou C.. (2019 ). Absence of Gut Microbiota Affects Lipid Metabolism in the Prefrontal Cortex of Mice. Neurol. Res.41, 1104–1112.

    Not in our library10.1080/01616412.2019.1675021

  26. 26.

    Chiang J. Y. (2009 ). Bile Acids: Regulation of Synthesis. J. Lipid Res. 50, 1955–1966.

    Not in our library10.1194/jlr.r900010-jlr20

  27. 27.

    Chittim C. L. Martínez Del Campo A. Balskus E. P. (2019 ). Gut Bacterial Phospholipase Ds Support Disease-Associated Metabolism by Generating Choline. Nat. Microbiol. 4, 155–163.

    Not in our library10.1038/s41564-018-0294-4

  28. 28.

    Cuchel M. Meagher E. A. du Toit Theron H. Blom D. J. Marais A. D. Hegele R. A.. (2013 ). Efficacy and Safety of a Microsomal Triglyceride Transfer Protein Inhibitor in Patients With Homozygous Familial Hypercholesterolaemia: A Single-Arm, Open-Label, Phase 3 Study. Lancet381(9860), 40–46.

    Not in our library10.1016/s0140-6736(12)61731-0

  29. 29.

    Cummings J. Pomare E. Branch W. Naylor C. Macfarlane G. (1987 ). Short Chain Fatty Acids in Human Large Intestine, Portal, Hepatic and Venous Blood. Gut 28, 1221–1227.

    Not in our library10.1136/gut.28.10.1221

  30. 30.

    Dalile B. Van Oudenhove L. Vervliet B. Verbeke K. (2019 ). The Role of Short-Chain Fatty Acids in Microbiota-Gut-Brain Communication. Nat. Rev. Gastroenterol. Hepatol. 16, 461–478.

    Not in our library10.1038/s41575-019-0157-3

  31. 31.

    de La Serre C. B. Ellis C. L. Lee J. Hartman A. L. Rutledge J. C. Raybould H. E.. (2010 ). Propensity to High-Fat Diet Induced Obesity in Rats Is Associated With Changes in the Gut Micro Biota and Gut Inflammation. Am. J. Physiol. Gastrointest. Liver Physiol.299(2), G440–G448.

    Not in our library10.1152/ajpgi.00098.2010

  32. 32.

    Delzenne N. M. Williams C. M. (2002 ). Prebiotics and Lipid Metabolism. Curr. Opin. Lipidol. 13, 61–67.

    Not in our library10.1097/00041433-200202000-00009

  33. 33.

    den Besten G. Lange K. Havinga R. van Dijk T. H. Gerding A. van Eunen K.. (2013 ). Gut-Derived Short-Chain Fatty Acids are Vividly Assimilated Into Host Carbohydrates and Lipids. Am. J. Physiol.-Gastrointest. Liver Physiol.305, G900–G910.

    Not in our library10.1152/ajpgi.00265.2013

  34. 34.

    Deng X. Ma J. Song M. Jin Y. Ji C. Ge W.. (2019 ). Effects of Products Designed to Modulate the Gut Microbiota on Hyperlipidaemia. Eur. J. Nutr.58 (7), 2713–2729.

    Not in our library10.1007/s00394-018-1821-z

  35. 35.

    Devkota S. Wang Y. Musch M. W. Leone V. Fehlner-Peach H. Nadimpalli A.. (2012 ). Dietary-Fat-Induced Taurocholic Acid Promotes Pathobiont Expansion and Colitis in Il10-/- Mice. Nature487, 104–108.

    Not in our library10.1038/nature11225

  36. 36.

    D’Mello C. Ronaghan N. Zaheer R. Dicay M. Le T. MacNaughton WK.. (2015 ). Probiotics Improve Inflammation-Associated Sickness Behavior by Altering Communication Between the Peripheral Immune System and the Brain. J. Neurosci.35(30), 10821–10830.

    Not in our library10.1523/jneurosci.0575-15.2015

  37. 37.

    Du Toit A. (2016 ). Microbiome: Restoring Healthy Growth in Infants. Nat. Rev. Microbiol. 14, 191.

    Not in our library10.1038/nrmicro.2016.31

  38. 38.

    Einarsson K. Hellstrm K. Kallner M. (1974 ). Bile Acid Kinetics in Relation to Sex, Serum Lipids, Body Weights, and Gallbladder Disease in Patients With Various Types of Hyperlipoproteinemia. J. Clin. Invest. 54, 1301–1311.

    Not in our library10.1172/jci107876

  39. 39.

    Erridge C. Attina T. Spickett C. M. Webb D. J. (2007 ). A High-Fat Mealinduces Low-Grade Endotoxemia: Evidence of a Novel Mechanism of Postprandial Inflammation. Am. J. Clin. Nutr. 86, 1286–1292.

    Not in our library10.1093/ajcn/86.5.1286

  40. 40.

    Ezzati M. Obermeyer Z. Tzoulaki I. Mayosi B. M. Elliott P. Leon D. A. (2015 ). Contributions of Risk Factors and Medical Care to Cardiovascular Mortality Trends. Nat. Rev. Cardiol. 12, 508–530.

    Not in our library10.1038/nrcardio.2015.82

  41. 41.

    Feingold K. R. Funk J. L. Moser A. H. Shigenaga J. K. Rapp J. H. Grunfeld C. (1995 ). Role for Circulating Lipoproteins in Protection From Endotoxin Toxicity. Infect. Immun. 63, 2041–2046.

    Not in our library10.1128/iai.63.5.2041-2046.1995

  42. 42.

    Fidélix M. Milenkovic D. Sivieri K. Cesar T. (2020 ). Microbiota Modulation and Effects on Metabolic Biomarkers by Orange Juice: A Controlled Clinical Trial. Food Funct.11 (2), 1599–1610.

    Not in our library10.1039/c9fo02623a

  43. 43.

    Flint H. J. Scott K. P. Louis P. Duncan S. H. (2012 ). The Role of the Gut Microbiota in Nutrition and Health. Nat. Rev. Gastroenterol. Hepatol. 9, 577–589.

    Not in our library10.1038/nrgastro.2012.156

  44. 44.

    Fouts D. E. Torralba M. Nelson K. E. Brenner D. A. Schnabl B. (2012 ). Bacterial Translocation and Changes in the Intestinal Microbiome in Mouse Models of Liver Disease. J. Hepatol. 56, 1283–1292.

    Not in our library10.1016/j.jhep.2012.01.019

  45. 45.

    Fu J. Bonder M. J. Cenit M. C. Tigchelaar E. F. Maatman A. Dekens J. A.. (2015 ). The Gut Microbiome Contributes to a Substantial Proportion of the Variation in Blood Lipids. Circ. Res.117, 817–824.

    Not in our library10.1161/circresaha.115.306807

  46. 46.

    Fukuda S. Ohno H. (2014 ). Gut Microbiome and Metabolic Diseases. Semin. Immunopathol. 36, 103–114.

    Not in our library10.1007/s00281-013-0399-z

  47. 47.

    Gao Z. Yin J. Zhang J. Ward R. E. Martin R. J. Lefevre M.. (2009 ). Butyrate Improves Insulin Sensitivity and Increases Energy Expenditure in Mice. Diabetes58, 1509–1517.

    Not in our library10.2337/db08-1637

  48. 48.

    Gargari G. Deon V. Taverniti V. Gardana C. Denina M. Riso P.. (2018 ). Evidence of Dysbiosis in the Intestinal Microbial Ecosystem of Children and Adolescents With Primary Hyperlipidemia and the Potential Role of Regular Hazelnut Intake. FEMS Microbiol. Ecol.94, 5.

    Not in our library10.1093/femsec/fiy045

  49. 49.
    Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 · 2018
    No notice
  50. 50.

    Ge H. Li X. Weiszmann J. Wang P. Baribault H. Chen J. L.. (2008 ). Activation of G Protein-Coupled Receptor 43 in Adipocytes Leads to Inhibition of Lipolysis and Suppression of Plasma Free Fatty Acids. Endocrinology149, 4519–4526.

    Not in our library10.1210/en.2008-0059

  51. 51.

    Ghanim H. Abuaysheh S. Sia C. L. Korzeniewski K. Chaudhuri A. Fernandez-Real J. M.. (2009 ). Increase in Plasma Endotoxin Concentrations and the Expression of Toll-Like Recep-Tors and Suppressor of Cytokine Signaling-3in Mononuclear Cells After a High-Fat, High-Carbohydrate Meal:Implications for Insulin Resistance. Diabetes Care32, 2281–2287.

    Not in our library10.2337/dc09-0979

  52. 52.

    Gordon D. J. Probstfield J. L. Garrison R. J. (1989 ). High-Density Lipoprotein Cholesterol and Cardiovascular Disease: Four Prospective American Studies. Circulation 79, 8–15.

    Not in our library10.1161/01.cir.79.1.8

  53. 53.

    Guerrero-Bonmatty R. Gil-Fernández G. Rodríguez-Velasco F. J. Espadaler-Mazo J. (2021 ). A Combination of Lactoplantibacillus Plantarum Strains CECT7527, CECT7528, and CECT7529 Plus Monacolin K Reduces Blood Cholesterol: Results From a Randomized, Double-Blind, Placebo-Controlled Study. Nutrients 13 (4), 1206.

    Not in our library10.3390/nu13041206

  54. 54.

    Guo J. Han X. Tan H. Huang W. You Y. Zhan J. (2019 ). Blueberry Extract Improves Obesity Through Regulation of the Gut Microbiota and Bile Acids via Pathways Involving FXR and TGR5. iScience 19, 676–690.

    Not in our library10.1016/j.isci.2019.08.020

  55. 55.

    Han S. Pan Y. Yang X. Da M. Wei Q. Gao Y.. (2019 ). Intestinal Microorganisms Involved in Colorectal Cancer Complicated With Dyslipidosis. Cancer Biol. Ther.20, 81–89.

    Not in our library10.1080/15384047.2018.1507255

  56. 56.

    Hardardóttir I. Grunfeld C. Feingold K. R. (1995 ). Effects of Endotoxin on Lipid Metabolism. Biochem. Soc. Trans. 23, 1013–1018.

    Not in our library10.1042/bst0231013

  57. 57.

    Harris H. W. Grunfeld C. Feingold K. R. Rapp J. H. (1990 ). Human Very Low Density Lipoproteins and Chylomicrons Can Protect Against Endotoxin-Induced Death in Mice. J. Clin. Invest. 86, 696–702.

    Not in our library10.1172/jci114765

  58. 58.

    He K. Hu Y. Ma H. Zou Z. Xiao Y. Yang Y.. (2016 ). Rhizoma Coptidis Alkaloids Alleviate Hyperlipidemia in B6 Mice by Modulating Gut Microbiota and Bile Acid Pathways. Biochim. Biophys. Acta1862, 1696–1709.

    Not in our library10.1016/j.bbadis.2016.06.006

  59. 59.

    Hersoug L. G. Mller P. Loft S. (2016 ). Gut Microbiota-Derived Lipopolysaccharide Uptake and Trafficking to Adipose Tissue: Implications for Inflammation and Obesity. Obes. Rev. 17, 297–312.

    Not in our library10.1111/obr.12370

  60. 60.

    Hold G. L. Schwiertz A. Aminov R. I. Blaut M. Flint H. J. (2003 ). Oligonucleotide Probes That Detect Quantitatively Significant Groups of Butyrate-Producing Bacteria in Human Feces. Appl. Environ. Microbiol. 69, 4320–4324.

    Not in our library10.1128/aem.69.7.4320-4324.2003

  61. 61.

    Hood L. (2012 ). Tackling the Microbiome. Science (New York N.Y.) 336, 1209.

    Not in our library10.1126/science.1225475

  62. 62.

    Huang W. C. Chen Y. M. Kan N. W. Ho C. S. Wei L. Chan C. H.. (2015 ). Hypolipidemic Effects and Safety of Lactobacillus Reuteri 263 in a Hamster Model of Hyperlipidemia. Nutrients7, 3767–3782.

    Not in our library10.3390/nu7053767

  63. 63.

    Huang Y. P. Gao S. X. Chen J. L. Albrecht E. Zhao R. Q. Yang X. J. (2017 ). Maternal Butyrate Supplementation Induces Insulin Resistance Associated With Enhanced Intramuscular Fat Deposition in the Offspring. Oncotarget 8, 13073–13084.

    Not in our library10.18632/oncotarget.14375

  64. 64.
    Theabrownin from Pu-erh tea attenuates hypercholesterolemia via modulation of gut microbiota and bile acid metabolism · 2019
    No notice
  65. 65.

    Insull W. Jr. (2006 ). Clinical Utility of Bile Acid Sequestrants in the Treatment of Dyslipidemia: A Scientifc Review. South Med. J. 99, 257–273.

    Not in our library10.1097/01.smj.0000208120.73327

  66. 66.

    Janssen A. W. Kersten S. (2015 ). The Role of the Gut Microbiota in Metabolic Health. FASEB J. 29, 3111–3123.

    Not in our library10.1096/fj.14-269514

  67. 67.

    Jiang C. Xie C. Li F. Zhang L. Nichols R. G. Krausz K. W.. (2015 ). Intestinal Farnesoid X Receptor Signaling Promotes Nonalcoholic Fatty Liver Disease. J. Clin. Invest.125, 386–402.

    Not in our library10.1172/jci76738

  68. 68.

    Kanneganti T. D. Dixit V. D. (2012 ). Immunological Complications of Obesity. Nat. Immunol. 13 (8), 707–712.

    Not in our library10.1038/ni.2343

  69. 69.

    Kao D. Roach B. Silva M. Beck P. Rioux K. Kaplan G. G.. (2017 ). Effect of Oral Capsule- vs Colonoscopy-Delivered Fecal Microbiota Transplantation on Recurrent Clostridium Difficile Infection: A Randomized Clinical Trial. JAMA318, 1985–1993.

    Not in our library10.1001/jama.2017.17077

  70. 70.

    Kim K. A. Lee I. A. Gu W. Hyam S. R. Kim D. H. (2014 ). β-Sitosterol Attenuates High-Fat Diet-Induced Intestinal Inflammation in Mice by Inhibiting the Binding of Lipopolysaccharide to Toll-Like Receptor 4 in the NF-κb Pathway. Mol. Nutr. Food Res. 58, 963–972.

    Not in our library10.1002/mnfr.201300433

  71. 71.

    Kim J. D. Yoon N. A. Jin S. Diano S. (2019 ). Microglial UCP2 Mediates Inflammation and Obesity Induced by High-Fat Feeding. Cell Metab. Nov 5 30 (5), 952–962.e5.

    Not in our library10.1016/j.cmet.2019.08.010

  72. 72.

    Kim Y. Yoon S. Lee S. B. Han H. W. Oh H. Lee W. J.. (2014 ). Fermentation of Soy Milk via Lactobacillus Plantarum Improves Dysregulated Lipid Metabolism in Rats on a High Cholesterol Diet. PloS One9, e88231.

    Not in our library10.1371/journal.pone.0088231

  73. 73.

    Koh A. B?ckhed F. (2020 ). From Association to Causality: The Role of the Gut Microbiota and Its Functional Products on Host Metabolism. Mol. Cell 78, 584–596.

    Not in our library10.1016/j.molcel.2020.03.005

  74. 74.

    Koh A. De Vadder F. Kovatcheva-Datchary P. Bäckhed F. (2016 ). From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites. Cell 165, 1332–1345.

    Not in our library10.1016/j.cell.2016.05.041

  75. 75.

    Komaroff A. L. (2018 ). The Microbiome and Risk for Atherosclerosis. JAMA 319, 2381–2382.

    Not in our library10.1001/jama.2018.5240

  76. 76.
    Fecal microbiota transplantation confers beneficial metabolic effects of diet and exercise on diet-induced obese mice · 2018
    No notice
  77. 77.

    LaRusso N. F. Korman M. G. Hoffman N. E. Hofmann A. F. (1974 ). Dynamics of the Enterohepatic Circulation of Bile Acids. Postprandial Serum Concentrations of Conjugates of Cholic Acid in Health, Cholecystectomized Patients, and Patients With Bile Acid Malabsorption. N. Engl. J. Med. 291, 689–692.

    Not in our library10.1056/nejm197410032911401

  78. 78.

    Lim S. Jeong J. Woo K. H. Han M. J. Kim H. (2015 ). Lactobacillus Sakei OK67 Ameliorates High-Fat Diet-Induced Blood Glucose Intolerance and Obesity in Mice by Inhibiting Gut Microbiota LPS Production and Inducing Colon Tight Junction Protein Expression. Nutr. Res. 36, 337–348.

    Not in our library10.1016/j.nutres.2015.12.001

  79. 79.
    Butyrate and Propionate Protect against Diet-Induced Obesity and Regulate Gut Hormones via Free Fatty Acid Receptor 3-Independent Mechanisms · 2012
    No notice
  80. 80.

    Liu F. Prabhakar M. Ju J. Long H. Zhou H. W. (2017 ). Effect of Inulin-Type Fructans on Blood Lipid Profile and Glucose Level: A Systematic Review and Meta-Analysis of Randomized Controlledtrials. Eur. J. Clin. Nutr. 71, 9–20.

    Not in our library10.1038/ejcn.2016.156

  81. 81.

    Li K. Zhang L. Xue J. Yang X. Dong X. Sha L.. (2019 ). Dietary Inulin Alleviates Diverse Stages of Type 2 Diabetes Mellitus via Anti-Inflammation and Modulating Gut Microbiota in Db/Db Mice. Food Funct.10 (4), 1915–1927.

    Not in our library10.1039/c8fo02265h

  82. 82.
    Aspirin eugenol ester regulates cecal contents metabolomic profile and microbiota in an animal model of hyperlipidemia · 2018
    Not checked
  83. 83.

    Mangiafico S. Costello-Boerrigter L. C. Andersen I. A. Cataliotti A. Burnett J. C. Jr. (2013 ). Neutral Endopeptidase Inhibition and the Natriuretic Peptide System: An Evolving Strategy in Cardiovascular Therapeutics. Eur. Heart J. 34, 886–893c.

    Not in our library10.1093/eurheartj/ehs262

  84. 84.

    Marques F. Z. Mackay C. R. Kaye D. M. (2018 ). Beyond Gut Feelings: How the Gut Microbiota Regulates Blood Pressure. Nat. Rev. Cardiol. 15 (1), 20–32.

    Not in our library10.1038/nrcardio.2017.120

  85. 85.

    McNeil N. I. (1984 ). The Contribution of the Large Intestine to Energy Supplies in Man. Am. J. Clin. Nutr. 39, 338–342.

    Not in our library10.1093/ajcn/39.2.338

  86. 86.

    Miller T. L. Wolin M. J. (1996 ). Pathways of Acetate, Propionate, and Butyrate Formation by the Human Fecal Microbial Flora. Appl. Environ. Microbiol. 62, 1589–1592.

    Not in our library10.1128/aem.62.5.1589-1592.1996

  87. 87.

    Mitchell S. Roso S. Samuel M. Pladevall-Vila M. (2016 ). Unmet Need in the Hyperlipidaemia Population With High Risk of Cardiovascular Disease: A Targeted Literature Review of Observational Studies. BMC Cardiovasc. Disord. 16, 74.

    Not in our library10.1186/s12872-016-0241-3

  88. 88.

    Miyata M. Takamatsu Y. Kuribayashi H. Yamazoe Y. (2009 ). Administration of Ampicillin Elevates Hepatic Primary Bile Acid Synthesis Through Suppression of Ileal Fibroblast Growth Factor 15 Expression. J. Pharmacol. Exp. Ther. 331, 1079–1085.

    Not in our library10.1124/jpet.109.160093

  89. 89.

    Moeller A. H. Degnan P. H. Pusey A. E. Wilson M. L. Hahn B. H. Ochman H. (2012 ). Chimpanzees and Humans Harbour Compositionally Similar Gut Enterotypes. Nat. Commun. 3, 1179.

    Not in our library10.1038/ncomms2159

  90. 90.

    Moreno-Indias I. Sánchez-Alcoholado L. Pérez-Martínez P. Andrés-Lacueva C. Cardona F. Tinahones F.. (2016 ). Red Wine Polyphenols Modulate Fecal Microbiota and Reduce Markers of the Metabolic Syndrome in Obese Patients. Food Funct.7, 1775–1787.

    Not in our library10.1039/c5fo00886g

  91. 91.

    Muccioli G. G. Naslain D. Bäckhed F. Reigstad C. S. Lambert D. M. Delzenne N. M.. (2010 ). The Endocannabinoid System Links Gut Microbiota to Adipogenesis. Mol. Syst. Biol.6, 392.

    Not in our library10.1038/msb.2010.46

  92. 92.

    Mulders R. J. de Git K. C. G. Schéle E. Dickson S. L. Sanz Y. Adan R. A. H. (2018 ). Microbiota in Obesity: Interactions With Enteroendocrine, Immune and Central Nervous Systems. Obes. Rev. 19 (4), 435–451.

    Not in our library10.1111/obr.12661

  93. 93.

    Na F. Liping Z. (2013 ). An Opportunistic Pathogen Isolated From the Gut of an Obese Human Causes Obesity in Germfree Mice. ISME J. 7, 880–884.

    Not in our library10.1038/ismej.2012.153

  94. 94.

    Nath A. Molnár M. A. Csighy A. Kőszegi K. Galambos I. Huszár K. P.. (2018 ). Biological Activities of Lactose-Based Prebiotics and Symbiosis With Probiotics on Controlling Osteoporosis, Blood-Lipid and Glucose Levels. Medicina54, 98.

    Not in our library10.3390/medicina54060098

  95. 95.

    Pan Y. Y. Zeng F. Guo W. L. Li T. T. Jia R. B. Huang Z. R.. (2018 ). Effect of Grifola Frondosa 95% Ethanol Extract on Lipid Metabolism and Gut Microbiota Composition in High-Fat Diet-Fed Rats. Food Funct.9, 6268–6278.

    Not in our library10.1039/c8fo01116h

  96. 96.

    Park Y. E. Kim M. S. Shim K. W. Kim Y.-I. Chu J. Kim B.-K.. (2020 ). Effects Of Lactobacillus Plantarum Q180 on Postprandial Lipid Levels and Intestinal Environment: A Double-Blind, Randomized, Placebo-Controlled, Parallel Trial. Nutrients12 (1), 255.

    Not in our library10.3390/nu12010255

  97. 97.

    Pathak P. Helsley R. N. Brown A. L. Buffa J. A. Choucair I. Nemet I.. (2020 ). Small Molecule Inhibition of Gut Microbial Choline Trimethylamine Lyase Activity Alters Host Cholesterol and Bile Acid Metabolism. Am. J. Physiol. Heart Circ. Physiol.318, H1474–H1486.

    Not in our library10.1152/ajpheart.00584.2019

  98. 98.

    Perry R. J. Peng L. Barry N. A. Cline G. W. Zhang D. Cardone R. L.. (2016 ). Acetate Mediates a Microbiome-Brain-β Cell Axis Promoting Metabolic Syndrome. Nature534(7606), 213–217.

    Not in our library10.1038/nature18309

  99. 99.

    Podda M. Zuin M. (1985 ). Effects of Fenofibrate on Biliary Lipids and Bile Acid Pool Size in Patients With Type IV Hyperlipoproteinemia. Atherosclerosis 55, 135–142.

    Not in our library10.1016/0021-9150(85)90092-9

  100. 100.

    Qian Y. Li M. Wang W. Wang H. Zhang Y. Hu Q.. (2019 ). Effects of Lactobacillus Casei YBJ02 on Lipid Metabolism in Hyperlipidemic Mice. J. Food Sci.84, 3793–3803.

    Not in our library10.1111/1750-3841.14787

  101. 101.

    Qin J. Li Y. Cai Z. Li S. Zhu J. Zhang F.. (2012 ). A Metagenome-Wide Association Study of Gut Microbiota in Type 2 Diabetes. Nature490, 55–60.

    Not in our library10.1038/nature11450

  102. 102.
    The impact of the gut microbiota on the reproductive and metabolic endocrine system · 2021
    No notice
  103. 103.

    Raal F. J. Santos R. D. Blom D. J. Marais A. D. Charng M. J. Cromwell W. C.. (2010 ). Mipomersen, an Apolipoprotein B Synthesis Inhibitor, for Lowering of LDL Cholesterol Concentrations in Patients With Homozygous Familial Hypercholesterolaemia: A Randomised, Double-Blind, Placebo-Controlled Trial. Lancet375(9719), 998–1006.

    Not in our library10.1016/s0140-6736(10)60284-x

  104. 104.

    Rabot S. Membrez M. Bruneau A. Gérard P. Harach T. Moser M.. (2010 ). Germ-Free C57BL/6J Mice are Resistant to High-Fat-Diet-Induced Insulin Resistance and Have Altered Cholesterol Metabolism. FASEB J.24, 4948–4959.

    Not in our library10.1096/fj.10-164921

  105. 105.

    Raetz C. R. H. Whitfield C. (2002 ). Lipopolysaccharide Endotoxins. Annu. Rev. Biochem. 71, 635–700.

    Not in our library10.1146/annurev.biochem.71.110601.135414

  106. 106.

    Repa J. J. Berge K. E. Pomajzl C. Richardson J. A. Hobbs H. Mangelsdorf D. J. (2002 ). Regulation of ATP-Binding Cassette Sterol Transporters ABCG5 and ABCG8 by the Liver X Receptors Alpha and Beta. J. Biol. Chem. 277, 18793–18800.

    Not in our library10.1074/jbc.m109927200

  107. 107.
    Bile salt biotransformations by human intestinal bacteria · 2006
    Not checked
  108. 108.

    Ridlon J. M. Kang D. J. Hylemon P. B. Bajaj J. S. (2014 ). Bile Acids and the Gut Microbiome. Curr. Opin. Gastroenterol. 30, 332–338.

    Not in our library10.1097/mog.0000000000000057

  109. 109.

    Rietschel E. T. Kirikae T. Schade F. U. Mamat U. Schmidt G. Loppnow H.. (1994 ). Bacterial Endotoxin: Molecular Relationships of Structure to Activity and Function. FASEB J.: Off. Publ. Fed. Am. Soc Exp. Biol.8, 217–225.

    Not in our library10.1096/fasebj.8.2.8119492

  110. 110.

    Rinott E. Youngster I. Yaskolka Meir A. Tsaban G. Zelicha H. Kaplan A.. (2021 ). Effects of Diet-Modulated Autologous Fecal Microbiota Transplantation on Weight Regain. Gastroenterology160 (1), 158–173.e10.

    Not in our library10.1053/j.gastro.2020.08.041

  111. 111.

    Roediger W. E. (1980 ). Role of Anaerobic Bacteria in the Metabolic Welfare of the Colonic Mucosa in Man. Gut 21, 793–798.

    Not in our library10.1136/gut.21.9.793

  112. 112.

    Rohr M. W. Narasimhulu C. A. Rudeski-Rohr T. A. Parthasarathy S. (2020 ). Negative Effects of a High-Fat Diet on Intestinal Permeability: A Review. Adv. Nutr. Jan 1 11 (1), 77–91.

    Not in our library10.1093/advances/nmz061

  113. 113.

    Royall D. Wolever T. M. Jeejeebhoy K. N. (1990 ). Clinical Significance of Colonic Fermentation. Am. J. Gastroenterol. 85 (10), 1307–1312.

    Not in our library

  114. 114.

    Russell D. W. (2003 ). The Enzymes, Regulation, and Genetics of Bile Acid Synthesis. Annu. Rev. Biochem. 72, 137–174.

    Not in our library10.1146/annurev.biochem.72.121801.161712

  115. 115.

    Russell D. W. Setchell K. D. (1992 ). Bile Acid Biosynthesis. Biochemistry 31, 4737–4749.

    Not in our library10.1021/bi00135a001

  116. 116.

    Samuel B. S. Shaito A. Motoike T. Rey F. E. Backhed F. Manchester J. K.. (2008 ). Effects of the Gut Microbiota on Host Adiposity Are Modulated by the Short-Chain Fatty-Acid Binding G Protein-Coupled Receptor, Gpr41. Proc. Natl. Acad. Sci.105, 16767–16772.

    Not in our library10.1073/pnas.0808567105

  117. 117.

    Sanz Y. Moya-Pérez A. (2014 ). Microbiota, Inflammation and Obesity. Adv. Exp. Med. Biol. 817, 291–317.

    Not in our library10.1007/978-1-4939-0897-4_14

  118. 118.

    Schmitt J. Kong B. Stieger B. Tschopp O. Schultze S. M. Rau M.. (2015 ). Protective Effects of Farnesoid X Receptor (FXR) on Hepatic Lipid Accumulation are Mediated by Hepatic FXR and Independent of Intestinal FGF15 Signal. Liver Int.35, 1133–1144.

    Not in our library10.1111/liv.12456

  119. 119.

    Shakappa D. Talari A. Rajkumar H. Shujauddin M. (2018 ). Hypolipidemic Effect of Red Gram (Cajanus Cajan L.) Prebiotic Oligosaccharides in Wistar NIN Rats. J. Diet Suppl. 15, 410–418.

    Not in our library10.1080/19390211.2017.1350246

  120. 120.

    Sharma S. Kurpad A. V. Puri S. (2016 ). Potential of Probiotics in Hypercholesterolemia: A Meta-Analysis. Indian J. Public Health 60, 280–286.

    Not in our library10.4103/0019-557x.195859

  121. 121.

    Shin W. Kim H. J. (2018 ). Intestinal Barrier Dysfunction Orchestrates the Onset of Inflammatory Host-Microbiome Cross-Talk in a Human Gut Inflammation-on-a-Chip. Proc. Natl. Acad. Sci. U.S.A. 115, E10539–E10547.

    Not in our library10.1073/pnas.1810819115

  122. 122.

    Singh D. P. Singh J. Boparai R. K. Mantri J. Khare S. Khardori P.. (2017 ). Isomalto-Oligosaccharides, a Prebiotic, Functionally Augment Green Tea Effects Against High Fat Diet-Induced Metabolic Alterations via Preventing Gut Dysbacteriosis in Mice. Pharmacol. Res.123, 103–113.

    Not in our library10.1016/j.phrs.2017.06.015

  123. 123.
    Fiber and Prebiotics: Mechanisms and Health Benefits · 2013
    No notice
  124. 124.

    Song J. J. Tian W. J. Kwok L. Y. Wang Y. L. Shang Y. N. Menghe B.. (2017 ). Effects of Microencapsulated Lactobacillus Plantarum LIP-1 on the Gut Microbiota of Hyperlipidaemic Rats. Br. J. Nutr.118, 481–492.

    Not in our library10.1017/s0007114517002380

  125. 125.

    Stancu C. S. Sanda G. M. Deleanu M. Sima A. V. (2014 ). Probiotics Determine Hypolipidemic and Antioxidant Effects in Hyperlipidemic Hamsters. Mol. Nutr. Food Res. 58, 559–568.

    Not in our library10.1002/mnfr.201300224

  126. 126.

    Stein E. A. Mellis S. Yancopoulos G. D. Stahl N. Logan D. Smith W. B.. (2012 ). Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol. N. Engl. J. Med.366(12), 1108–1118.

    Not in our library10.1056/nejmoa1105803

  127. 127.

    Sun S. S. Wang K. Ma K. Bao L. Liu H. W.. (2019 ). An Insoluble Polysaccharide From the Sclerotium of Poria Cocos Improves Hyperglycemia, Hyperlipidemia and Hepatic Steatosis in Ob/Ob Mice via Modulation of Gut Microbiota. Chin. J. Nat. Med.17(1), 3–14.

    Not in our library10.1016/s1875-5364(19)30003-2

  128. 128.

    Sun R. Yang N. Kong B. Cao B. Feng D. Yu X.. (2017 ). Orally Administered Berberine Modulates Hepatic Lipid Metabolism by Altering Microbial Bile Acid Metabolism and the Intestinal FXR Signaling Pathway. Mol. Pharmacol.91 (2), 110–122.

    Not in our library10.1124/mol.116.106617

  129. 129.

    Swann J. R. Want E. J. Geier F. M. Spagou K. Wilson I. D. Sidaway J. E.. (2011 ). Systemic Gut Microbial Modulation of Bile Acid Metabolism in Host Tissue Compartments. Proc. Natl. Acad. Sci. U.S.A.108 (Suppl 1), 4523–4530.

    Not in our library10.1073/pnas.1006734107

  130. 130.

    Tazoe H. Otomo Y. Kaji I. Tanaka R. Karaki S. I. Kuwahara A. (2008 ). Roles of Short-Chain Fatty Acids Receptors,GPR41 and GPR43 on Colonic Functions. J. Physiol. Pharmacol. 59 Suppl 2, 251–262.

    Not in our library

  131. 131.

    Thomas A. M. Hart S. N. Kong B. Fang J. Zhong X. B. Guo G. L. (2010 ). Genome-Wide Tissue-Specific Farnesoid X Receptor Binding in Mouse Liver and Intestine. Hepatology (Baltimore Md) 51, 1410–1419.

    Not in our library10.1002/hep.23450

  132. 132.
    Structural Alteration of Gut Microbiota during the Amelioration of Human Type 2 Diabetes with Hyperlipidemia by Metformin and a Traditional Chinese Herbal Formula: a Multicenter, Randomized, Open Label Clinical Trial · 2018
    No notice
  133. 133.

    Townsend N. Nichols M. Scarborough P. Rayner M. (2015 ). Cardiovascular Disease in Europe- Epidemiological Update 2015. Eur. Heart J. 36, 2696–2705.

    Not in our library10.1093/eurheartj/ehv428

  134. 134.

    Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration (2010 ). Sarwar, N; Sandhu, MS. Triglyceride-Mediated Pathways and Coronary Disease: Collaborative Analysis of 101 Studies. Lancet 375, 1634–1639.

    Not in our library10.1016/s0140-6736(10)60545-4

  135. 135.

    Velagapudi V. R. Hezaveh R. Reigstad C. S. Gopalacharyulu P. Yetukuri L. Islam S.. (2010 ). The Gut Microbiota Modulates Host Energy and Lipid Metabolism in Mice. J. Lipid Res.51, 1101–1112.

    Not in our library10.1194/jlr.m002774

  136. 136.

    Vergnes L. Lee J. M. Chin R. G. Auwerx J. Reue K. (2013 ). Diet1 Functions in the FGF15/19 Enterohepatic Signaling Axis to Modulate Bile Acid and Lipid Levels. Cell Metab. 17, 916–928.

    Not in our library10.1016/j.cmet.2013.04.007

  137. 137.

    Wahlström A. Sayin S. I. Marschall H. U. Bäckhed F. (2016 ). Intestinal Crosstalk Between Bile Acids and Microbiota and Its Impact on Host Metabolism. Cell Metab. 24, 41–50.

    Not in our library10.1016/j.cmet.2016.05.005

  138. 138.

    Wang Z. Klipfell E. Bennett B. J. Koeth R. Levison B. S. Dugar B.. (2011 ). Gut Flora Metabolism of Phosphatidylcholine Promotes Cardiovascular Disease. Nature472, 57–63.

    Not in our library10.1038/nature09922

  139. 139.

    Wang L. Li C. Huang Q. Fu X. (2020 ). Polysaccharide From Rosa Roxburghii Tratt Fruit Attenuates Hyperglycemia and Hyperlipidemia and Regulates Colon Microbiota in Diabetic Db/Db Mice. J. Agric. Food Chem. 68, 147–159.

    Not in our library10.1021/acs.jafc.9b06247

  140. 140.

    Wang P. Li D. Ke W. Liang D. Hu X. Chen F. (2020 ). Resveratrol-Induced Gut Microbiota Reduces Obesity in High-Fat Diet-Fed Mice. Int. J. Obes. (Lond.) 44, 213–225.

    Not in our library10.1038/s41366-019-0332-1

  141. 141.

    Wang Y. Shou J. W. Li X. Y. Zhao Z. X. Fu J. He C. Y.. (2017 ). Berberine-Induced Bioactive Metabolites of the Gut Microbiota Improve Energy Metabolism. Metabolism70, 72–84.

    Not in our library10.1016/j.metabol.2017.02.003

  142. 142.

    Watanabe M. Houten S. M. Mataki C. Christoffolete M. A. Kim B. W. Sato H.. (2006 ). Bile Acids Induce Energy Expenditure by Promoting Intracellular Thyroid Hormone Activation. Nature (London)439, 484–489.

    Not in our library10.1038/nature04330

  143. 143.

    Weng H. Endo K. Li J. Kito N. Iwai N. (2015 ). Induction of Peroxisomes by Butyrate-Producing Probiotics. PloS One 10, e0117851.

    Not in our library10.1371/journal.pone.0117851

  144. 144.

    Wu W. K. Chen C. C. Liu P. Y. Panyod S. Liao B. Y. Chen P. C.. (2019 ). Identification of TMAO-Producer Phenotype and Host-Diet-Qut Dysbiosis by Carnitine Challenge Test in Human and Germ-Freemice. Gut68, 1439–1449.

    Not in our library10.1136/gutjnl-2018-317155

  145. 145.

    Wu T. R. Lin C. S. Chang C. J. Lin T. L. Martel J. Ko Y. F.. (2019 ). Gut Commensal Parabacteroides Goldsteinii Plays a Predominant Role in the Anti-Obesity Effects of Polysaccharides Isolated From Hirsutella Sinensis. Gut68, 248–262.

    Not in our library10.1136/gutjnl-2017-315458

  146. 146.

    Xiao S. Zhang Z. Chen M. Zou J. Jiang S. Qian D.. (2019 ). Xiexin Tang Ameliorates Dyslipidemia in High-Fat Diet-Induced Obese Rats via Elevating Gut Microbiota-Derived Short Chain Fatty Acids Production and Adjusting Energy Metabolism. J. Ethnopharmacol.241, 112032.

    Not in our library10.1016/j.jep.2019.112032

  147. 147.

    Xu W. T. Nie Y. Z. Yang Z. Lu N. H. (2016 ). The Crosstalk Between Gut Microbiota and Obesity and Related Metabolic Disorders. Future Microbiol. 11, 825–836.

    Not in our library10.2217/fmb-2015-0024

  148. 148.

    Yadav R. Khan S. H. Mada S. B. Meena S. Kapila R. Kapila S. (2019 ). Consumption of Probiotic Lactobacillus Fermentum MTCC: 5898-Fermented Milk Attenuates Dyslipidemia, Oxidative Stress, and Inflammation in Male Rats Fed on Cholesterol-Enriched Diet. Probiotics Antimicrob. Proteins 11, 509–518.

    Not in our library10.1007/s12602-018-9429-4

  149. 149.

    Yan S. Huang J. Chen Z. Jiang Z. Li X. Chen Z. (2016 ). Metabolomics in Gut Microbiota: Applications Ano Challenges. Sci. Bull. 61, 1151–1153.

    Not in our library10.1007/s11434-016-1142-7

  150. 150.

    Yu L. Zhou X. Duan H. Chen Y. Cui S. Guo R.. (2021 ). Synergistic Protective Effects of Different Dietary Supplements Against Type 2 Diabetes via Regulating Gut Microbiota. J. Med. Food24 (3), 319–330.

    Not in our library10.1089/jmf.2020.4759

  151. 151.

    Zeyda M. Stulnig T. M. (2007 ). Adipose Tissue Macrophages. Immunol. Lett. 112 (2), 61–672.

    Not in our library10.1016/j.imlet.2007.07.003

  152. 152.

    Zhang X. Chen Y. Zhu J. Zhang M. Ho C. T. Huang Q.. (2018 ). Metagenomics Analysis of Gut Microbiota in a High Fat Diet-Induced Obesity Mouse Model Fed With (-)-Epigallocatechin 3-O-(3-O-Methyl) Gallate (EGCG3″Me). Mol. Nutr. Food Res.Jul62 (13), e1800274.

    Not in our library10.1002/mnfr.201800274

Cited by papers we hold 2

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.